Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Down 18.6% in September

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was the recipient of a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 131,600 shares, a decrease of 18.6% from the August 31st total of 161,600 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 123,400 shares, the short-interest ratio is currently 1.1 days.

Hedge Funds Weigh In On Telomir Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of TELO. Beaird Harris Wealth Management LLC lifted its stake in Telomir Pharmaceuticals by 212.9% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after purchasing an additional 9,950 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $241,000. Finally, Suncoast Equity Management acquired a new stake in shares of Telomir Pharmaceuticals in the first quarter valued at approximately $126,000.

Telomir Pharmaceuticals Price Performance

Shares of Telomir Pharmaceuticals stock opened at $6.82 on Friday. Telomir Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $20.72. The business has a 50 day simple moving average of $5.07 and a two-hundred day simple moving average of $5.58.

Telomir Pharmaceuticals (NASDAQ:TELO) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.05) earnings per share for the quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.